Amit Rakhit who is Chief Medical and Portfolio Officer, will become Chief Medical & Portfolio Officer and Head of R&D on Apr. 1, 2019 (news posted on March 29 2019).
Create an alert
to follow the executive moves at Ovid Therapeutics.
Zambon has acquired Breath Therapeutics (posted on Jul 29, 2019).
Cognizant has announced the acquisition of Zenith Technologies (posted on Jun 18, 2019).
Dassault Systemes has announced the acquisition of Medidata Solutions (posted on Jun 14, 2019).
Ovid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress | Ovid Therapeutics Inc.
Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome | Ovid Therapeutics Inc.
Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020 | Ovid Therapeutics Inc.
Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium | Ovid Therapeutics Inc.
Ovid Therapeutics Reports First Quarter 2019 Financial Results | Ovid Therapeutics Inc.
Ovid Therapeutics has 1,290 competitors including Aldeyra Therapeutics (United States (USA)), Janssen Research & Development (United States (USA)) and Alltech (United States (USA)).
Learn about your clients' org charts. Understand their industries and their competitors.
View the executives' biographies. Contact the executives through our email platform.
Select key words to follow your clients. Receive alerts when executive movements happen.
File your clients in folders. Add private notes. Download our data in Excel on your PC.